Biogen will present new findings at the Alzheimer’s Association International Conference (AAIC) 2026, set for July 12–15 in London. This includes data from the Phase 2 CELIA study of diranersen, an investigational tau-targeting ASO, as well as additional analyses of LEQEMBI (lecanemab).